- Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
- Immunocore to present at the Jefferies Global Healthcare Conference
- Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
- Immunocore reports first quarter financial results and provides a business update
- EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
- Immunocore announces upcoming presentation and posters at ASCO 2024
- Immunocore to present at upcoming investor conferences
- Immunocore presented two posters at CROI 2024
More ▼
Key statistics
On Monday, Immunocore Holdings PLC (IMCR:NSQ) closed at 39.28, 18.87% above the 52 week low of 33.05 set on Jun 28, 2024.
52-week range
Open | 39.86 |
---|---|
High | 39.91 |
Low | 38.27 |
Bid | 25.18 |
Offer | 39.86 |
Previous close | 39.78 |
Average volume | 399.75k |
---|---|
Shares outstanding | 50.01m |
Free float | 44.13m |
P/E (TTM) | -- |
Market cap | 1.95bn USD |
EPS (TTM) | -1.20 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼